aTyr Pharma Updates Timeline for Phase 3 Study of Pulmonary Sarcoidosis Drug

The biotechnology company announced a revised schedule for receiving regulatory feedback on its planned clinical trial for efzofitimod, a treatment targeting pulmonary sarcoidosis.

1 Sept, 20:36 — 1 Sept, 20:36

Post Share

Sources

Showing 1 of 1 sources

taiwan-newsMostly Factual1d ago

aTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis - taiwannews.com.tw

aTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis taiwannews.com.tw

Read full article →

aTyr Pharma Updates Timeline for Phase 3 Study of Pulmonary Sarcoidosis Drug

Sources

aTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis - taiwannews.com.tw

Related Stories

Arsenal Sells Martinelli to Al Hilal for Club-Record Fee

ICE Agent Charged With Lying Over Minneapolis Shooting

Israeli Minister Unveils Plan for Palestinian Relocation From Gaza

Lindsay Clancy Murder Trial Faces Deadlock After Jury Fails to Reach Verdict